

Chimerix Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 19-Feb-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 11

 Phase 3 Clinical..... 12

 Discovery..... 18

[Return to Table of Contents](#)

Chimerix Inc

COMPANY OVERVIEW

Company Name	Chimerix Inc
Parent Company Name	Chimerix Inc
Website	http://www.chimerix.com/
Country	US
Number of Drugs in Active Development	6
Number of Inactive Drugs	5
Number of Patents as Owner	18
Number of Patents as Third Party	1
Number of Deals	9
Key Indications	Cytomegalovirus infection,Adenovirus infection,BK virus infection,Influenza virus infection,Polyomavirus infection,DNA virus infection,Dengue virus infection,Epstein Barr virus infection,Hepatitis,Herpes simplex virus infection,Monkeypox virus infection,Mycobacterium tuberculosis infection,Plasmodium infection,Vaccinia virus infection,Variola virus infection
Key Target-based Actions	Hepatitis C virus NS5B polymerase inhibitor,Cytochrome P450 reductase inhibitor,P-Glycoprotein inhibitor,Acetaldehyde dehydrogenase stimulator,B-lymphocyte antigen CD20 stimulator,BCL2 gene inhibitor,Cytosine deaminase stimulator,Glutathione S-transferase stimulator,Homeobox protein NANOG stimulator,Integrin alpha-4/beta-1 antagonist,P-Glycoprotein 3 stimulator,POU domain 5 transcription factor 1 stimulator,Reverse transcriptase inhibitor,SOX transcription factor 2 stimulator
Key Technologies	Small molecule therapeutic,Oral formulation,Parenteral formulation unspecified,Lipid,Prodrug,Nucleotide and derivatives,Oral liquid formulation,Oral sustained release formulation,Tablet formulation,Drug

COMPANY PROFILE

SUMMARY

Chimerix Inc began operations in the third quarter of 2002, to commercialize the proprietary chemistry developed in the laboratory of Dr Karl Hostettler at the University of California San Diego and the Veterans Administration Hospital in San Diego, CA. The company uses its proprietary lipid conjugate technology to enhance the oral availability and delivery of antiviral drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions. Chimerix intends to develop drug candidates through proof-of-concept clinical trials before seeking to outlicense clinical candidates to pharmaceutical companies for late stage clinical trials, distribution, and marketing.

LICENSING AGREEMENTS

In May 2006, Chimerix acquired Dr Leroy Townsend's chemical lead antiviral and oncology compound library from the University of Michigan. The company would add promising compounds to its technology platform, or license them to other pharmaceutical and biotechnology companies.

EARLY R&D

By May 2010, the company was also investigating compounds for malaria and dengue fever.

By August 2009, the company was investigating hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza programs.

By May 2004, Chimerix was using its technology to create drug candidates for hepatitis C virus infection from known inhibitors of the viral polymerase.

FINANCIAL

[Return to Table of Contents](#)



In December 2013, the company was selected to list on the NASDAQ Biotechnology Index following annual re-ranking of the list, effective from December 23, 2013.

In October 2013, Chimerix filed a registration statement with the US SEC for certain stockholders to offer shares of common stock in an underwritten public offering. The company would not receive any proceeds from the sale of shares. Later that month, the company announced pricing of 2,476,995 shares of its common stock at a public price of \$16.50 each. Underwriters were granted a 30-day option to buy up to an additional 371,549 shares of common stock to cover over-allotments. The offering was expected to close on October 23, 2013; later that month, the secondary offering was closed.

In June 2013, the company was to be added to the Russell 2000, Russell 3000 and Russell Global Indexes on June 28, 2013, as a part of the annual reconstitution of the Russell indexes.

In March 2013, Chimerix filed a Form S-1 with the US SEC for a proposed IPO of its common stock. In April 2013, the company priced the initial public offering of 7,320,000 common stock shares at \$14.00 each. At that time, the underwriters were granted a 30-day option to buy up to an additional 1,098,000 common stock shares to cover over-allotments, if any. The shares were traded under the symbol 'CMRX' on the NASDAQ Global market and the offering was expected to close on April 16, 2013. Later that month, the company completed an IPO 8,418,000 shares of its common stock. In May 2013, the company reported that the gross proceeds were \$117.9 million.

In February 2011, the company raised \$45 million from the closing of a series F financing.

In August 2009, Chimerix raised \$16.1 million from the closing of a series E financing.

In February 2007, Chimerix raised \$23.1 million from the private placement of series D preferred stock.

In November 2004, Chimerix raised \$11 million private placement of its series C preferred stock. The funds would augment a grant from the NIH for \$36.1 million awarded to Chimerix for the development of CMX-001 and would allow the company to accelerate its cytomegalovirus infection, multi-drug resistant HIV-1 infection and viral hepatitis programs.

In September 2003, Chimerix closed a \$3.1 million preferred stock private financing. The funds were to be used to support Chimerix's drug development programs for HIV and HCV, and to continue to support the company's R&D activities.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	5	5	10
Respiratory disease	2	1	3
Gastrointestinal disease	1	2	3
Inflammatory disease	1	2	3

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	5
Discontinued	1
No Development Reported	4

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	3	0	0	0	3
Drug - Asset Divestment	0	0	1	0	1
Drug - CRADA	1	0	0	0	1
Drug - Screening/Evaluation	1	0	0	0	1
Drug - Early Research/Development	1	0	0	0	1
Drug - Development/Commercialization License	1	0	1	0	2

[Return to Table of Contents](#)

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	1	11
Inflammatory disease	0	1
Gastrointestinal disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	1	2
Phase 2	0	3
Phase 1	0	5
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	0	1	1
Endocrine disease	2	1	3
Gastrointestinal disease	6	1	7
Genitourinary disease	3	0	3
Hematological disease	2	1	3
Degeneration	1	0	1
Andrology	2	0	2
Immune disorder	3	1	4
Musculoskeletal disease	1	0	1
Neoplasm	3	1	4

[Return to Table of Contents](#)



Ocular disease	1	0	1
Metabolic disorder	0	1	1
Neurological disease	1	1	2
Respiratory disease	3	0	3
Infectious disease	19	0	19
Inflammatory disease	6	0	6
Fatigue	1	0	1
Gynecology and obstetrics	1	0	1
Surgical procedure	0	1	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

brincidofovir

brincidofovir SNAPSHOT

Drug Name	brincidofovir
Key Synonyms	brincidofovir
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Herpes simplex virus infection;DNA virus infection;Cytomegalovirus infection;Variola virus infection;BK virus infection;Polyomavirus infection;Epstein Barr virus infection;Adenovirus infection;Monkeypox virus infection;Vaccinia virus infection
Target-based Actions	
Other Actions	Viral replication inhibitor;Synergist
Technologies	Oral liquid formulation;Tablet formulation;Oral formulation;Lipid;Small molecule therapeutic
Last Change Date	17-Feb-2014

brincidofovir DEVELOPMENT PROFILE

SUMMARY

Chimerix, under broad patent rights from the University of California San Diego (UCSD), is developing brincidofovir (CMX-001, HDP-CDV, 1-O-hexadecyloxy-propyl-cidofovir), an oral cidofovir derivative which acts as a dsDNA replication inhibitor, for the potential prevention and treatment of smallpox infections and complications resulting from smallpox vaccination, cytomegalovirus (CMV), adeno, BK virus, herpes simplex, Epstein Barr and polyoma virus infections, ,,,. In August 2013, a phase III SUPPRESS trial for prevention of CMV infection in HSCT patients was initiated in the US. In January 2009, a phase I/II trial for BK virus was initiated ; in November 2011, data were reported. In January 2011, a phase II trial was initiated for adenovirus infection, and at that time, the drug was in a phase I trial for polyomavirus infection . In July 2011, a second phase II trial for adenovirus infection was initiated ; by September 2013, top-line data had been reported. In May 2012, Chimerix had completed an 'End of Phase II' meeting with the FDA. In July 2012, the company planned to conduct additional studies to assess the prevention of hemorrhagic cystitis in HSCT recipients and BK virus associated nephropathy in kidney transplant recipients, and to provide further evidence of the lack of nephrotoxicity of brincidofovir. In October 2011, the company was seeking to outlicense co-development rights to brincidofovir.

In January 2009, a multi-dose, phase I/II trial was initiated in stem cell and kidney transplant recipients with BK virus viruria ; however, by September 2010 the study was discontinued due to difficulty in recruiting subjects.

[Return to Table of Contents](#)


The UCSD is also investigating a series of oral cidofovir derivatives, and has undertaken preclinical studies on an earlier formulation of brincidofovir.

brincidofovir DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Chimerix Inc	Cytomegalovirus infection	US	Phase 3 Clinical	23-Aug-2013
Chimerix Inc	Adenovirus infection	US	Phase 2 Clinical	07-Jan-2011
Chimerix Inc	BK virus infection	US	Phase 2 Clinical	06-Jan-2009
Chimerix Inc	Epstein Barr virus infection	US	Phase 1 Clinical	31-Jan-2011
Chimerix Inc	Herpes simplex virus infection	US	Phase 1 Clinical	31-Jan-2011
Chimerix Inc	Polyomavirus infection	US	Phase 1 Clinical	03-Jan-2011
Chimerix Inc	Variola virus infection	US	Phase 1 Clinical	01-Aug-2006
Chimerix Inc	DNA virus infection	US	Clinical	07-Jan-2011
Chimerix Inc	Vaccinia virus infection	US	Clinical	19-Mar-2009
Chimerix Inc	Monkeypox virus infection	US	Discovery	06-May-2009
Chimerix Inc	Papovavirus infection	US	Discontinued	24-Sep-2010

brincidofovir CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
444805-28-1	1
	
Name	Type
brincidofovir	PINN; USAN
CMX-001	Research Code
1-O-hexadecyloxypropyl-CDV	

[Return to Table of Contents](#)

Name	Type
1-O-hexadecyloxy-propyl-cidofovir	
HDP-CDV	

brincidofovir DRUG NAMES

Names	Type
1-O-hexadecyloxy-propyl-cidofovir	
anti-infective (smallpox/Herpes simplex/polyoma/adeno/cyto megalovirus infections), Chimerix 1-O-hexadecyloxypropyl-CDV	
brincidofovir	PINN, USAN
HDP-CDV	
CMX-001	Research Code

brincidofovir CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Cytomegalovirus infection											
0	0	1	2	0	1	0	0	0	0	1	3
Adenovirus infection											
0	0	0	0	0	1	0	0	0	1	0	2
Variola virus infection											
0	0	0	0	0	0	0	2	0	0	0	2
Viral infection											
0	0	0	0	0	0	0	2	0	0	0	2
Herpes simplex virus infection											
0	0	0	0	0	0	1	1	0	0	1	1
DNA virus infection											
0	0	0	0	0	1	0	0	0	0	0	1

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	2	0	3	1	6	0	2	2	13

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

brincidofovir DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Chimerix Inc	3	0	1	0	4
US Government	0	0	3	0	3
Gilead Sciences Inc	1	0	0	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	2	0	2
Drug - CRADA	1	0	1
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Chimerix Inc	12	0	12
University of California	2	0	2
Roche Holding AG	2	0	2
St Louis University	1	0	1
Vestiar Research Inc	0	1	1
Gilead Sciences Inc	1	1	2
Vical Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	6
Component of Combination	2
Formulation	2
Process	2
General interest	2
Product	1
Tentative	1
Product (derivative)	1

[Return to Table of Contents](#)

dengue virus targeting compounds, Chimerix

dengue virus targeting compounds, Chimerix SNAPSHOT

Drug Name	dengue virus targeting compounds, Chimerix
Key Synonyms	
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Dengue virus infection
Target-based Actions	
Other Actions	Unspecified drug target;Antiviral
Technologies	Small molecule therapeutic;Parenteral formulation unspecified
Last Change Date	12-Mar-2013

dengue virus targeting compounds, Chimerix DEVELOPMENT PROFILE

SUMMARY

Chimerix is investigating therapeutics, presumed to be nucleoside analogs, for the potential prevention and treatment of dengue virus infection. In January 2011, screening for the lead compound was underway ; in March 2013, this was still the case.

dengue virus targeting compounds, Chimerix DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Chimerix Inc	Dengue virus infection	US	Discovery	04-Jan-2011

dengue virus targeting compounds, Chimerix DRUG NAMES

Names	Type
dengue virus targeting compounds, Chimerix	

[Return to Table of Contents](#)



influenza A and B virus targeting compounds, Chimerix

influenza A and B virus targeting compounds, Chimerix SNAPSHOT

Drug Name	influenza A and B virus targeting compounds, Chimerix
Key Synonyms	
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Influenza virus infection
Target-based Actions	
Other Actions	Antiviral;Unspecified drug target
Technologies	Small molecule therapeutic;Parenteral formulation unspecified
Last Change Date	12-Mar-2013

influenza A and B virus targeting compounds, Chimerix DEVELOPMENT PROFILE

SUMMARY

Chimerix is investigating compounds, presumed to be nucleoside analogs for the potential prevention and treatment of influenza A and B viral infections. By January 2011, the company had identified active compounds against influenza. In March 2013, screening for the lead compound was underway.

influenza A and B virus targeting compounds, Chimerix DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Chimerix Inc	Influenza virus infection	US	Discovery	04-Jan-2011

influenza A and B virus targeting compounds, Chimerix DRUG NAMES

Names	Type
influenza A and B virus targeting compounds, Chimerix	

[Return to Table of Contents](#)

antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix

antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix SNAPSHOT

Drug Name	antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix
Key Synonyms	
Originator Company	iThemba Pharmaceuticals Pty Ltd
Active Companies	iThemba Pharmaceuticals Pty Ltd;Chimerix Inc
Inactive Companies	Medicines for Malaria Venture
Highest Status	Discovery
Active Indications	Plasmodium infection
Target-based Actions	
Other Actions	Unspecified drug target;Antiparasitic
Technologies	Small molecule therapeutic
Last Change Date	08-Mar-2013

antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix DEVELOPMENT PROFILE

SUMMARY

iThemba Pharmaceuticals and Chimerix are investigating small molecule therapeutics for the potential

The drug was previously investigated in collaboration with Medicines For Malaria Venture. However, no further development was reported.

antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Chimerix Inc	Plasmodium infection	US	Discovery	02-Apr-2009
iThemba Pharmaceuticals Pty Ltd	Plasmodium infection	South Africa	Discovery	06-May-2010
Medicines for Malaria Venture	Plasmodium infection	Switzerland	No Development Reported	31-Oct-2010

[Return to Table of Contents](#)



antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix DRUG NAMES

Names	Type
antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix	

antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Chimerix Inc	2	0	0	0	2
Medicines for Malaria Venture	0	0	1	0	1
iThemba Pharmaceuticals Pty Ltd	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Screening/Evaluation	1	0	1
Drug - Early Research/Development	1	0	1

[Return to Table of Contents](#)

nucleoside analogs (hepatitis C virus infection), Chimerix

nucleoside analogs (hepatitis C virus infection), Chimerix SNAPSHOT

Drug Name	nucleoside analogs (hepatitis C virus infection), Chimerix
Key Synonyms	
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hepatitis
Target-based Actions	Hepatitis C virus NS5B polymerase inhibitor
Other Actions	Antiviral
Technologies	Small molecule therapeutic;Nucleotide and derivatives
Last Change Date	07-Mar-2013

nucleoside analogs (hepatitis C virus infection), Chimerix DEVELOPMENT PROFILE

SUMMARY

Chimerix is investigating a series of nucleoside analogs, including HCV polymerase inhibitors, for the potential treatment of HCV infection. In January 2011, the company planned to select the lead compound for preclinical development. At that time, it also planned to identify additional back-up compounds ; in March 2013, this was still the case.

The company is also developing the drug CMX-157 for chronic HBV infection.

nucleoside analogs (hepatitis C virus infection), Chimerix DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Chimerix Inc	Hepatitis	US	Discovery	31-Dec-2009

nucleoside analogs (hepatitis C virus infection), Chimerix DRUG NAMES

Names	Type
nucleoside analogs (hepatitis C virus infection), Chimerix	

[Return to Table of Contents](#)

Mycobacterium tuberculosis infection targeting compounds, Chimerix

Mycobacterium tuberculosis infection targeting compounds, Chimerix SNAPSHOT

Drug Name	Mycobacterium tuberculosis infection targeting compounds, Chimerix
Key Synonyms	
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Mycobacterium tuberculosis infection
Target-based Actions	
Other Actions	Unspecified drug target;Antibacterial
Technologies	Small molecule therapeutic
Last Change Date	11-Mar-2013

Mycobacterium tuberculosis infection targeting compounds, Chimerix DEVELOPMENT PROFILE

SUMMARY

Chimerix Inc is investigating compounds, presumed to be nucleoside analogs, for the potential prevention and treatment of tuberculosis. In January 2011, screening for the lead compound was underway ; in March 2013, this was still the case.

Mycobacterium tuberculosis infection targeting compounds, Chimerix DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Chimerix Inc	Mycobacterium tuberculosis infection	US	Discovery	04-Jan-2011

Mycobacterium tuberculosis infection targeting compounds, Chimerix DRUG NAMES

Names	Type
Mycobacterium tuberculosis infection targeting compounds, Chimerix	

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

